July 15, 2024
Estrogen Blockers Market

Non-Hormonal Contraceptives Is Fastest Growing Segment Fueling The Growth Of Estrogen Blockers Market

The global Estrogen Blockers Market is estimated to be valued at US$ 15.02 Bn in 2023 and is expected to exhibit a CAGR of 6.5% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Overview:

Estrogen blockers helps inhibit the action of estrogens and block their effects in the body. They are commonly used as a form of contraception and for treating hormone-sensitive cancers such as breast cancer. They provide an effective method of birth control without causing significant side effects.

Market key trends:

One of the key trends in the estrogen blockers market is the rising demand for non-hormonal contraceptive options. The increasing prevalence of side effects associated with hormonal contraceptives such as weight gain, mood swings, and increased risk of blood clots is driving women to look for safer alternatives. Non-hormonal contraceptives such as estrogen blockers do not contain artificial hormones and have relatively fewer side effects. They work by blocking the natural hormone estrogen required for conception without causing systemic effects on the body. Their rising popularity can be attributed to the growing health consciousness among consumers and need for safer contraception.

Segment Analysis

The estrogen blockers market is segmented on the basis of type, application and end user. Based on type, the market is bifurcated into tamoxifen, aromatase inhibitors and clomiphene. The aromatase inhibitors segment currently dominates the market owing to its efficacy and minimal side effect profile. Aromatase inhibitors work by blocking the aromatase enzyme responsible for estrogen production resulting in estrogen suppression.

Key Takeaways

Global Estrogen Blockers Market Size is expected to witness high growth, exhibiting CAGR of 6.5% over the forecast period, due to increasing prevalence of hormone-sensitive cancers including breast cancer.

Regional analysis

North America currently dominates the estrogen blockers market owing to rising incidences of breast cancer and growing awareness regarding hormonal therapies. Furthermore, presence of key players and availability of advanced treatment options also contribute to the large share of the region in the global market.

Key players

Key players operating in the estrogen blockers market are Pfizer Inc., Novartis AG, AstraZeneca PLC, Eli Lilly and Company, Merck & Co., Inc., Bristol Myers Squibb Company, Johnson & Johnson, Sanofi S.A., AbbVie Inc., GlaxoSmithKline plc. Pfizer Inc. and AstraZeneca PLC hold major share in the global market due to their broad product portfolio and strong geographic presence.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it